Biotech pharma

AbInitio Bio

Website
Founded 2026Origin source ↗Checked 2026-09-15

Overview

Abinitio Bio builds foundation models for biomanufacturing, validated against wet lab data. Our first model, Echo, predicts manufacturing outcomes more accurately than standard models, and any pharma or CDMO can adapt it to their own workflow instantly. By making process decisions that take 6-18 months today in hours, we help teams avoid the cost of delay on a single program.

Company description As recorded 2026-11-08

Founders & team

Daniel Mukasa

Founder/CEO

Founder & CEO at AbInitio Bio (YC P26). Postdoctoral Fellow at MIT focused on AI and drug discovery. Previously AI/ML intern at Merck working on antibody therapeutic design. PhD in Applied Physics and Materials Science from Caltech.

Founder profile As recorded 2026-09-15

Nisha Gopal

Founder

Founder CSO at Abinitio Bio (YC P26). Biochemist with 14 years of experience, Stanford PhD, former research scientist at the The Broad Institute of Harvard and MIT

Founder profile As recorded 2026-09-15
2team members reported
Source-reported As recorded 2026-09-15

Founded 2026 · Source

News & product activity

Sources & observations

Y Combinator

Profile depthverified profile
Website observationwebsite reachable
Last website check2026-11-11
Location · source statedBoston, MA, USA
Pricing evidenceNo pricing page confirmed
Maturity: Not assessed · 3 of 6 areas documented

Source-based assessment · automated evidence rules

The retained text does not establish product availability or customer use.

Maturity is an evidence-based assessment, not a success rating. It may understate the current stage where evidence is limited. Coverage records documented areas, not a complete or independently audited company history.

Stage definitions
independent websitesource corroborationreachable websitedescriptive evidenceclassified market and modelsourced peoplesourced founding year